Subtopic Deep Dive
HIV and Anal Cancer Outcomes
Research Guide
What is HIV and Anal Cancer Outcomes?
HIV and Anal Cancer Outcomes examines how HIV status affects chemoradiation tolerance, recurrence risks, and survival rates in anal squamous cell carcinoma patients on antiretroviral therapy.
Anal cancer incidence rises in HIV-positive populations due to HPV co-infection and immunosuppression (Glynne-Jones et al., 2014, 484 citations). Cohort studies assess immune recovery biomarkers and treatment outcomes post-ART initiation. Over 20 papers from 2005-2021 analyze survival disparities, with guidelines emphasizing multidisciplinary care.
Why It Matters
Rising HIV-associated anal cancers demand tailored chemoradiation protocols to reduce recurrence in immunocompromised patients (Glynne-Jones et al., 2014, 258 citations). Equity improves through ART-optimized strategies, as HIV+ patients show higher incidence yet similar response rates to nigro regimen when CD4 counts exceed 200 (Uronis and Bendell, 2007). Shamseddine et al. (2021) highlight immunotherapy potential for HPV-driven tumors in HIV contexts, impacting global oncology guidelines.
Key Research Challenges
Immunosuppression Toxicity Risks
HIV+ patients face heightened chemoradiation toxicity due to low CD4 counts, complicating standard dosing (Glynne-Jones et al., 2014, 355 citations). Balancing ART and oncologic therapy requires cohort data on immune recovery. Biomarkers for tolerance prediction remain underdeveloped.
Recurrence Rate Disparities
Higher locoregional recurrence occurs in HIV+ anal cancer despite comparable initial responses (Glynne-Jones et al., 2017, 178 citations). Long-term survival data show persistent gaps post-ART. HPV typing aids risk stratification but lacks prospective validation.
Screening Efficacy Gaps
Anal cytology screening in HIV+ cohorts detects intraepithelial neoplasia but misses invasive cancers early (Fox, 2005, 153 citations; Leeds, 2016, 162 citations). Consensus on frequency and high-risk thresholds is absent. Integration with HPV typing needs randomized trials.
Essential Papers
Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up
Rob Glynne‐Jones, Per J. Nilsson, C. Aschele et al. · 2014 · European Journal of Surgical Oncology · 484 citations
Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer
Panagiotis Balermpas, Yvonne Michel, Jens Wagenblast et al. · 2013 · British Journal of Cancer · 301 citations
Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up
Rob Glynne‐Jones, Per J. Nilsson, C. Aschele et al. · 2014 · Radiotherapy and Oncology · 258 citations
Squamous cell carcinoma of the anus (SCCA) is a rare cancer but its incidence is increasing throughout the world, and is particularly high in the human immunodeficiency virus positive (HIV+) popula...
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial
Rob Glynne‐Jones, David Sebag‐Montefiore, Helen Meadows et al. · 2017 · The Lancet Oncology · 178 citations
Anal Cancer: An Overview
Hope E. Uronis, Johanna C. Bendell · 2007 · The Oncologist · 177 citations
Learning Objectives After completing this course, the reader will be able to: Discuss the epidemiology of and the risk factors for anal cancer.Outline standard treatment for anal cancer and describ...
Tumor Immunity and Immunotherapy for HPV-Related Cancers
Achraf A. Shamseddine, Bharat Burman, Nancy Y. Lee et al. · 2021 · Cancer Discovery · 166 citations
Abstract Human papillomavirus (HPV) infection drives tumorigenesis in the majority of cervical, oropharyngeal, anal, and vulvar cancers. Genetic and epidemiologic evidence has highlighted the role ...
Dose-Painted Intensity-Modulated Radiation Therapy for Anal Cancer: A Multi-Institutional Report of Acute Toxicity and Response to Therapy
Lisa A. Kachnic, Henry Tsai, John J. Coen et al. · 2010 · International Journal of Radiation Oncology*Biology*Physics · 166 citations
Reading Guide
Foundational Papers
Start with Glynne-Jones et al. (2014, 484 citations) for ESMO guidelines on HIV-high incidence and multidisciplinary care; Uronis and Bendell (2007, 177 citations) for epidemiology and risk factors in HIV contexts.
Recent Advances
Glynne-Jones et al. (2017, 178 citations) on response timing post-chemoradiation; Shamseddine et al. (2021, 166 citations) on immunotherapy for HPV-HIV tumors.
Core Methods
Chemoradiation (nigro regimen: 5-FU/mitomycin + RT); anal cytology/HPV typing for screening; TIL assessment for response prediction (Balermpas et al., 2013); cohort survival analysis.
How PapersFlow Helps You Research HIV and Anal Cancer Outcomes
Discover & Search
Research Agent uses searchPapers and exaSearch to find HIV-anal cancer studies, revealing Glynne-Jones et al. (2014, 484 citations) as top-cited via citationGraph. findSimilarPapers expands to HPV-HIV cohorts from 250M+ OpenAlex papers.
Analyze & Verify
Analysis Agent applies readPaperContent on Glynne-Jones et al. (2014) abstracts for HIV incidence data, verifies survival stats with CoVe chain-of-verification, and runs PythonAnalysis for meta-analysis of CD4 thresholds using pandas on cohort sizes. GRADE grading scores guideline evidence as high for multidisciplinary care.
Synthesize & Write
Synthesis Agent detects gaps in HIV+ recurrence data via contradiction flagging across guidelines, generates exportMermaid diagrams of treatment pathways. Writing Agent uses latexEditText, latexSyncCitations for Glynne-Jones papers, and latexCompile for oncology review manuscripts.
Use Cases
"Extract survival rates from HIV+ anal cancer cohorts and plot Kaplan-Meier curves."
Research Agent → searchPapers('HIV anal cancer survival') → Analysis Agent → readPaperContent(Glynne-Jones 2017) → runPythonAnalysis(pandas survival data, matplotlib KM plots) → researcher gets CSV-exported curves and stats.
"Draft LaTeX review on HIV impact on chemoradiation for anal SCC."
Synthesis Agent → gap detection(HIV recurrence) → Writing Agent → latexEditText(structure review) → latexSyncCitations(Glynne-Jones et al. 2014) → latexCompile → researcher gets compiled PDF with synced references.
"Find code for anal cancer risk models in HIV datasets."
Research Agent → searchPapers('HIV anal cancer') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts for biomarker analysis from related HPV repos.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ HIV-anal papers) → citationGraph → GRADE all → structured report on outcomes. DeepScan applies 7-step CoVe to verify toxicity claims from Glynne-Jones (2014). Theorizer generates hypotheses on ART-CD4 interactions from Shamseddine (2021) literature.
Frequently Asked Questions
What defines HIV and Anal Cancer Outcomes research?
It studies HIV's influence on chemoradiation tolerance, recurrence, and survival in anal cancer via cohort analyses and immune biomarkers (Glynne-Jones et al., 2014).
What methods assess outcomes in HIV+ patients?
Cohort studies track CD4 recovery on ART, HPV typing, and response to nigro chemoradiation; anal cytology screens precursors (Fox, 2005; Leeds, 2016).
What are key papers?
Glynne-Jones et al. (2014, 484 citations) provide ESMO guidelines noting high HIV incidence; Uronis and Bendell (2007) overview risks and treatments.
What open problems exist?
Prospective trials for de-escalated therapy in high-CD4 HIV+ patients; validated biomarkers for recurrence beyond TILs (Balermpas et al., 2013).
Research Colorectal and Anal Carcinomas with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching HIV and Anal Cancer Outcomes with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Colorectal and Anal Carcinomas Research Guide